{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T16:38:48Z","timestamp":1782232728105,"version":"3.54.5"},"reference-count":23,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2016,3,1]],"date-time":"2016-03-01T00:00:00Z","timestamp":1456790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["redjournal.org","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1016\/j.ijrobp.2015.10.011","type":"journal-article","created":{"date-parts":[[2015,11,10]],"date-time":"2015-11-10T19:45:15Z","timestamp":1447184715000},"page":"657-666","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":76,"title":["Outcomes Associated With 3 Treatment Schedules of High-Dose-Rate Brachytherapy Monotherapy for Favorable-Risk Prostate Cancer"],"prefix":"10.1016","volume":"94","author":[{"given":"Maha Saada","family":"Jawad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua T.","family":"Dilworth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary S.","family":"Gustafson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Wallace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alvaro","family":"Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter Y.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"Krauss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2015.10.011_bib1","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1001\/jama.294.10.1233","article-title":"Comparison of conventional-dose vs. high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: A randomized controlled trial","volume":"294","author":"Zietman","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.ijrobp.2015.10.011_bib2","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.ijrobp.2007.06.054","article-title":"Long-term results of the M.D. Anderson randomized dose-escalation trial for prostate cancer","volume":"70","author":"Kuban","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2015.10.011_bib3","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/S0360-3016(98)00406-4","article-title":"Acute morbidity reduction using 3DCRT for prostate carcinoma: A randomized study","volume":"43","author":"Koper","year":"1999","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2015.10.011_bib4","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/sj.pcan.4500910","article-title":"Comparison of late gastrointestinal and genitourinary toxicity of prostate cancer patients undergoing intensity-modulated versus conventional radiotherapy using localized fields","volume":"10","author":"Jani","year":"2007","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.ijrobp.2015.10.011_bib5","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1097\/COC.0b013e3181b9cd2f","article-title":"High-dose-rate brachytherapy: An excellent accelerated hypofractionated treatment for favorable prostate cancer","volume":"33","author":"Martinez","year":"2010","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2015.10.011_bib6","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/S0360-3016(03)00132-9","article-title":"What hypofractionated protocols should be tested for prostate cancer?","volume":"56","author":"Fowler","year":"2003","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2015.10.011_bib7","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0360-3016(00)01463-2","article-title":"Phase II prospective study of the use of conformal high-dose-rate brachytherapy as monotherapy for the treatment of favorable-risk prostate cancer: A feasibility report","volume":"49","author":"Martinez","year":"2001","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2015.10.011_bib8","first-page":"245","article-title":"Irradiation of localized prostatic carcinoma with a combination of high-dose-rate iridium-192 brachytherapy and external beam radiotherapy with three target definitions and dose levels inside the prostate gland","volume":"47","author":"Borghede","year":"1997","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2015.10.011_bib9","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1016\/j.ijrobp.2007.05.002","article-title":"Customized dose prescription for permanent prostate brachytherapy: Insights from a multicenter analysis of dosimetry outcomes","volume":"69","author":"Stone","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2015.10.011_bib10","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.ijrobp.2005.07.981","article-title":"Biologically effective dose\u00a0values for prostate brachytherapy: Effects of PSA failure and posttreatment biopsy results","volume":"64","author":"Stock","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2015.10.011_bib11","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/j.ijrobp.2004.08.014","article-title":"High-dose-rate intensity-modulated radiotherapy with external beam radiotherapy for prostate cancer: California enocurietherapy 10-year results","volume":"61","author":"Demanes","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2015.10.011_bib12","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/0360-3016(93)90546-8","article-title":"Concurrent treatment planning for outpatient high-dose-rate prostate template implants","volume":"27","author":"Edmunson","year":"2003","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2015.10.011_bib13","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.ijrobp.2006.04.029","article-title":"Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference","volume":"65","author":"Roach","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2015.10.011_bib14","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0360-3016(03)01578-5","article-title":"Toxicity after three-dimensional radiotherapy for prostate cancer with RTOG 9406 dose level IV","volume":"58","author":"Michalski","year":"2004","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2015.10.011_bib15","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.ijrobp.2011.06.004","article-title":"Preliminary analysis of 3D-CRT vs. IMRT on the high dose arm of RTOG 0126 prostate cancer trial: Toxicity report","volume":"81","author":"Michalski","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2015.10.011_bib16","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.ijrobp.2008.04.063","article-title":"Role of intensity-modulated radiotherapy in reducing toxicity in dose escalation for localized prostate cancer","volume":"73","author":"Al-Mamgani","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2015.10.011_bib17","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.ijrobp.2004.12.017","article-title":"Phase II dose escalation study of image-guided adaptive radiotherapy for prostate cancer: Use of dose-volume constraints to achieve rectal isotoxicity","volume":"63","author":"Vargas","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2015.10.011_bib18","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.radonc.2013.09.025","article-title":"High-dose-rate brachytherapy alone given as two or one fraction to patients for locally advanced prostate cancer: Acute toxicity","volume":"110","author":"Hoskin","year":"2014","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2015.10.011_bib19","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/S0360-3016(99)00069-3","article-title":"American Brachytherapy Society (ABS) recommendations for transperineal permanent brachytherapy of prostate cancer","volume":"44","author":"Nag","year":"1999","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2015.10.011_bib20","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1002\/(SICI)1097-0142(19991101)86:9<1877::AID-CNCR32>3.0.CO;2-5","article-title":"The national cancer database report on increased use of brachytherapy for the treatment of patients with prostate carcinoma in the U.S","volume":"86","author":"Mettlin","year":"1999","journal-title":"Cancer"},{"key":"10.1016\/j.ijrobp.2015.10.011_bib21","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1200\/JCO.2004.10.062","article-title":"The changing face of low-risk prostate cancer: Trends in clinical presentation and primary management","volume":"22","author":"Cooperberg","year":"2004","journal-title":"J Clinic Oncol"},{"key":"10.1016\/j.ijrobp.2015.10.011_bib22","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/S0360-3016(00)00550-2","article-title":"Five-year biochemical outcome and toxicity with transperineal CT-planned permanent I-125 prostate implantation for patients with localized prostate cancer","volume":"47","author":"Zelefsky","year":"2000","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2015.10.011_bib23","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1097\/01.ju.0000113299.34404.22","article-title":"High-dose-rate brachytherapy as prostate cancer monotherapy reduces toxicity compared to low-dose-rate palladium seeds","volume":"171","author":"Grills","year":"2004","journal-title":"J Urol"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301615265765?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301615265765?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,17]],"date-time":"2018-09-17T20:57:47Z","timestamp":1537217867000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301615265765"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,3]]}},"alternative-id":["S0360301615265765"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2015.10.011","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2016,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Outcomes Associated With 3 Treatment Schedules of High-Dose-Rate Brachytherapy Monotherapy for Favorable-Risk Prostate Cancer","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2015.10.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}